This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Ionis Pharmaceuticals (IONS) and Rhythm Pharmaceuticals (RYTM)

Tipranks - Tipranks - Tue Jun 16, 6:52AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA), Ionis Pharmaceuticals (IONS) and Rhythm Pharmaceuticals (RYTM) with bullish sentiments.

Claim 55% Off TipRanks

Teva Pharmaceutical (TEVA)

In a report released today, Chris Schott from J.P. Morgan maintained a Buy rating on Teva Pharmaceutical. The company’s shares closed last Friday at $34.63.

According to TipRanks.com, Schott is a 4-star analyst with an average return of 4.6% and a 56.2% success rate. Schott covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Johnson & Johnson, and Merck & Company. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $42.38 average price target, implying a 21.7% upside from current levels. In a report issued on June 1, Piper Sandler also reiterated a Buy rating on the stock with a $42.00 price target.

See the top stocks recommended by analysts >>

Ionis Pharmaceuticals (IONS)

In a report issued on June 12, Michael Ulz from Morgan Stanley reiterated a Buy rating on Ionis Pharmaceuticals, with a price target of $130.00. The company’s shares closed last Friday at $73.28.

According to TipRanks.com, Ulz is a 2-star analyst with an average return of 0.1% and a 41.4% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Kyverna Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

Ionis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $107.06, representing a 45.0% upside. In a report issued on May 29, TipRanks – Google also upgraded the stock to Buy with a $85.00 price target.

Rhythm Pharmaceuticals (RYTM)

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $149.00. The company’s shares closed last Friday at $88.38.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 4.5% and a 56.0% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Ultragenyx Pharmaceutical, and Bicara Therapeutics Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rhythm Pharmaceuticals with a $138.43 average price target, a 57.9% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $130.00 price target.

Read More on TEVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).